



Pioneering cellular medicines for women's health

ISCT ANZ || July 2026

Dr Vera Evtimov
Director of Operations

Targeting Ovarian Cancer and Endometriosis

STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD. ACN: 602 297 807

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements do not relate strictly to historical or current facts and may be accompanied by words such as 'could,' 'would,' 'may,' 'potentially,' 'suggest,' 'believes,' 'expects,' 'should,' 'intends,' 'plans,' 'forecasts,' and similar words or expressions.

Such statements involve substantial risks and uncertainties, not all of which may be known at the time. All statements contained in this presentation, other than statements of historical fact, including without limitation statements regarding our strategy, research and development plans, collaborations, future operations, future financial position, future revenues, projected costs, pricing, prospects, plans, and objectives of management, are forward-looking statements. Not all forward-looking statements in this presentation are explicitly identified as such.

The Company does not warrant any of the forward-looking statements in this presentation, and investors are advised to interpret such statements in the context of other available sources of information and with the assistance of expert advisors as appropriate.

Many factors could cause the actual results of the Company to differ materially from the results expressed or implied herein, and you should not place undue reliance on the forward-looking statements. Drug development is inherently risky, and only a small proportion of research and development programs lead to a marketed product. Factors which could change the Company's expected outcomes include, without limitation, our ability to: advance the development of our programs, and to do so within any timelines that may be indicated herein; the safety and efficacy of our drug development candidates; our ability to replicate experimental data; the

ongoing validity of patents covering our drug development candidates, and our freedom to operate under third party intellectual property; our ability to obtain necessary regulatory approvals; our ability to enter into and maintain partnerships, collaborations, and other business relationships necessary to the progression of our drug development candidates; changes in the competitive landscape pertaining to our drug development candidates; the timely availability of necessary capital to pursue our business objectives; changes in the public policy environment in one or more countries in which we operate or may seek to operate which disfavor our business; our ability to attract and retain qualified personnel; changes from anticipated levels of customer acceptance of existing and new products and services; and other factors, including the COVID-19 pandemic and the conflicts in Ukraine and Middle East.

Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, and although they reflect our current views as at the date of this presentation, there can therefore be no assurance that such expectations will prove to be correct. The Company has no obligation as a result of this presentation to pursue any specific strategy or plan outlined herein, or to deliver any specific outcome that may be implied or inferred.

Any forward-looking statements contained in this presentation speak only as of the date this presentation is made, and we expressly disclaim any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

Cartherics at a Glance

Cartherics is a late pre-clinical stage cell therapy company developing 'off-the-shelf' iPSC-NK treatments for solid cancers and endometriosis



- Based in Notting Hill
- Commenced operations Jan 2016
- Currently ~30 staff




- Operating from a dedicated 1,800m² purpose-built facility
- Recently upgraded cleanrooms



- 'Off-the-shelf' platform, using gene-edited iPSCs to produce immune cells with enhanced function
- 17 issued patents over 6 families


Cartherics: Cell Therapy Platform

Enables the rapid development of a diverse range of products and immune cell types




STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

A Scalable and Robust iPSC-Derived CAR-NK Platform



STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

Multi Billion-Dollar Solid Tumour Market




STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

CTH-401: Lead Product Candidate

First TAG-72 CAR-NK cell therapy

iPSCs gene-editing using CRISPR/Cas9


- **TAG-72 CAR knock-in**
 - Complements normal NK cell killing functions
- **DGK α ζ gene knock-outs**
 - Enhance anti-tumoral efficacy



Tumour-associated glycoprotein-72 (TAG-72)


- Well-validated tumour target
- Found on many adenocarcinomas including ovarian, gastric, colorectal, pancreatic cancers

Image: Ovarian cancer biopsy with TAG-72 staining (brown) by immunohistochemistry (Ponnusamy et al 2007)




STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

Clinical scale manufacturing: One vial of iPSC into >20 billion CTH-401 cells



STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

CTH-401: Clear, De-Risked Path to First-in-Human Trials



STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

CTH-501: Second Product Candidate

First CAR-NK Cell Therapy for TF in Cancer and Endometriosis


iPSCs gene-edited using CRISPR/Cas9

TF CAR knock-in

- Complements normal NK cell killing functions

Tissue Factor (TF)


- Found on many adenocarcinomas including ovarian, gastric, colorectal, pancreatic cancers
- Well-established expression in patients with endometriosis



STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

CTH-501: TF CAR-iNK Cells Target Cancer & Endometriosis


Cancer 3D model




Cancer spheroid
TF CAR iNK
E:T = 1:2

Endometriosis 3D model

Unedited iNK cells



TF CAR-iNK cells




Endometriosis spheroids + iNK cells
E:T = 4:1


STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

Challenges for Adoptive Cell Therapy in Solid tumours


1 Tumor heterogeneity & antigen escape



2 T-cell trafficking and infiltration



3 Immunosuppressive tumor microenvironment




STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

How Cartherics is Tackling These Challenges



Engaged a Stanford spinout (iollo)



DAYS

- ~20,000 genes analysed
- 11 CRISPR screens through meta-analysis
- 20 top-scoring candidates selected
- Deep mechanistic and IP evaluation
- 5 final candidates prioritised
 - ✓ Synergy
 - ✓ Favourable FTO position
 - ✓ Development feasibility
- **2 candidates:** clearest IP ready for immediate development
- **3 additional** validated targets, manageable IP


STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

CTH-502: Third Product Candidate

AI-designed CAR-NK cell therapy for Solid Tumours

iPSCs gene-edited using CRISPR/Cas9


- **Bispecific CAR knock-in**
 - Complements normal NK cell killing functions
- **Novel gene-edits identified by Quinn**
 - To reduce immune evasion
 - To combat immunosuppressive TME
 - To enhance tumour homing
 - To remodel the TME



STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

Our Pipeline: A Phased Approach for Clinical Strength

A Deliberate Strategy:
Validate the Platform, Then Unleash its Full Potential



STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

A Solid Foundation Built for Clinical Execution and Growth

Platform



Capability



Facility



Team



STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

Contact Details

Dr Vera Evtimov

Director of Operations
vera.evtimov@cartherics.com

CARTHERICS PTY LTD
12 Ferntree Place
Notting Hill VIC 3168
AUSTRALIA
(ACN 602 297 807)



CARtherics



November 2025